Clinical Trial Update: Risk-Adapted Therapy of Acute Myeloid Leukemia of Adults (18-60 Years) According to the Cytogenetic Result [Phase 3]

View source ↗

Summary

Phase 3 study evaluating risk-adapted therapy for adults with acute myeloid leukemia (ages 18-60) based on cytogenetic risk; the trial status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Snippet

Sponsor: University of Ulm | Conditions: Acute Myeloid Leukemia | Phase 3 | Status: COMPLETED